Drug intelligence / Profile preview

bioengineered staphylococcus epidermidis

Development stage: Unknown
Lead developer: Azitra
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Topical

Overview

Bioengineered *Staphylococcus epidermidis* is a live biotherapeutic product (LBP) being developed by Azitra, Inc., in collaboration with The Jackson Laboratory. This microbiome-based therapy utilizes a genetically modified strain of *S. epidermidis*, a common skin commensal bacterium, to produce and secrete bioactive antimicrobial compounds. These compounds are specifically designed to inhibit the growth of *Staphylococcus aureus*, including methicillin-resistant strains (MRSA), which are primary drivers of skin infections and exacerbations in conditions like atopic dermatitis. By leveraging the natural skin-colonizing properties of *S. epidermidis*, the therapy aims to restore microbial balance and provide a localized defense mechanism against pathogens. The program has received support from the U.S. Department of Defense to develop natural defense mechanisms against skin infections.

Targets

PGN (Peptidoglycan)AIP (Staphylococcus aureus accessory gene regulator autoinducing peptide)

Beyond the preview

Go deeper on bioengineered staphylococcus epidermidis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bioengineered staphylococcus epidermidis.

Explore the full profile